Recently Approved

January 2007
Pharmaceutical Representative;Jan2007, Vol. 37 Issue 1, p14
The article reports on recently approved drugs in the United States as of January 2007. The United States Food and Drug Administration has approved donepezil HCl tablets for severe Alzheimer's disease. Boehringer Ingelheim Corp.'s Parkinson's disease drug Mirapex (pramipexole dihydrochloride) has been approved for the treatment of moderate to severe primary restless legs syndrome.


Related Articles

  • New indication for Requip calms restless legs.  // Drug Topics;5/16/2005, Vol. 149 Issue 10, p6 

    This article reports that the U.S. Food and Drug Administration has approved GlaxoSmithKline PLC's Ropinirole drug for the treatment of moderate to severe primary restless legs syndrome in adults.

  • COMPANY SPOTLIGHT -- Schwarz Pharma.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p19 

    The article features Schwarz Pharma, a company engaged in research and development, production, marketing, and distribution of pharmaceutical products. It has a drug development team engaged in developing drugs for the treatment of neurological and urological disorders. The company's products...

  • COMPANY SPOTLIGHT – Pfizer.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p28 

    The article presents profile of pharmaceutical company Pfizer Inc. It talks about the company's announcement regarding the positive results of its Phase III study for Lyrica, or pregabalin, in patients with restless legs syndrome (RLS). It also talks about the company's involvement in the...

  • Pregabailn Versus Pramipexole for Restless Legs Syndrome. Williams, Glenn // Neurology Reviews;Jun2012, Vol. 20 Issue 6, p16 

    The article informs about a study which shows the high efficacy of alpha-2 delta ligand pregabalin over dopamine agonist pramipexole for the treatment of restless legs syndrome mentioning that pregabalin show less augmentation rate as compared to pramipexole.

  • 10 NEUROLOGIC DISORDERS.  // Monthly Prescribing Reference;Nov2014, Vol. 30 Issue 11, p186 

    The article offers information on several drugs from pharmaceutical companies which are used to treat various neurologic disorders including Alzheimer's disease, restless legs syndrome, and seizure disorders. Among the drugs discussed include Aricept from Eisai Co. Ltd., Horizant from XenoPort,...

  • Xenoport Drops Spasticity Drug, Reboots Horizant. Powers, Marie // BioWorld Today;5/21/2013, Vol. 24 Issue 97, p1 

    The article reports on the decline in shares of biopharmaceutical company Xenoport Inc. after the company decided to terminate its late stage arbaclofen placarbil (AP) program in spasticity due to multiple sclerosis (MS). AP was mentioned to be an oral, transported prodrug of the R-isomer of...

  • GSK breached marketing code. Dyer, Owen // BMJ: British Medical Journal (International Edition);8/19/2006, Vol. 333 Issue 7564, p368 

    The article reports on the pharmaceutical company GlaxoSmithKline (GSK). GSK has been ruled in breach of industry marketing rules after the company was found to have used a patients' support Web site to promote an unlicensed drug for the controversial condition known as restless leg syndrome, or...

  • Pramipexole (Mirapex) for Restless Legs Syndrome. Davis, Courtney J.; Golding, Jeremy // American Family Physician;4/15/2007, Vol. 75 Issue 8, p1239 

    The article discusses the safety and effectiveness of pramipexole for the treatment of restless legs syndrome (RLS). It is recommended that patients should be given the lowest effective dose to minimize risk of daytime somnolence. It is stated that approximately 60% of patients receiving...

  • Gabapentin Enacarbil Extended-Release Tablets (Horizant). Elliott, William T.; Chan, James // Internal Medicine Alert;5/29/2011, Vol. 33 Issue 10, p78 

    The article focuses on the clinical indications, dosage, and potential advantages and disadvantages of Gabapentin enacarbil, a nondopaminergic tablet approved by the U.S. Food and Drug Administration (FAD) for the treatment of restless legs syndrome (RLS).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics